Abstract

In recent years, anthracycline-containing single, alternating or "hybrid' combination chemotherapy regimens have achieved superior results in the treatment of patients with advanced Hodgkin's disease to those with single regimens of the MOPP type. A number of studies also suggest the superiority of combined modality regimens with chemotherapy and radiation therapy to chemotherapy alone among this group of patients. These studies and recent analyses of prognostic factors among patients treated with these current treatment approaches have been the subjects of this brief review.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call